Craniopharyngioma
Craniopharyngioma
CONNECT1905: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Ages: 1 Year to 25 Years
Adamantinomatous Craniopharyngioma (ACP) is a highly debilitating pediatric brain tumor that lacks medical anti-tumor therapies. Current therapy, which depends largely on surgery and radiation, is associated with poor quality of life and becomes more challenging and risky in the setting of recurrent ...More
CONNECT2108: MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Ages: 1 Year to 25 Years
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug w ...More
Contact Us
To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Medulloblastoma New Diagnosis
- Medulloblastoma Relapse / Refractory
- Low Grade Glioma New Diagnosis
- Low Grade Glioma Relapse / Refractory
- DIPG/High Grade Glioma New Diagnosis
- DIPG/High Grade Glioma Relapse / Refractory
- Ependymoma New Diagnosis
- Ependymoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- ATRT
- Germ Cell Tumor
- Choroid Plexus Tumor
- All Other Brain and Spinal Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2023 Cincinnati Children's Hospital Medical Center. All rights reserved.
